Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 6/2022

29.08.2022 | Review

Obesity, a challenge in the management of inflammatory bowel diseases

verfasst von: Mohsen Rajabnia, Shideh Moftakhari Hajimirzaei, Mohammad Reza Hatamnejad, Shabnam Shahrokh, Shaghayegh Baradaran Ghavami, Maryam Farmani, Naghmeh Salarieh, Nastaran Ebrahimi, Nesa Kazemifard, Azam Farahanie, Ghazal Sherkat, Hamid Asadzadeh Aghdaei

Erschienen in: Immunologic Research | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Obesity, a morbid condition snowballing in the world, may cause many health issues in healthy and ill people. Many disorders are known to be influenced by obesity, mainly in a catastrophic way, including inflammatory bowel disease (IBD). Many studies sought to determine the effects that obesity prompts IBD. Some of them indicate that obesity is associated with poor outcomes. There is no consistency regarding the correlation between obesity and IBDs due to the equivocal nature of obesity and the shortage of extensive and reliable investigations. However, to a worldwide consensus, obesity has a unique disease burden and can cause poor prognosis when it accompanies other ailments. Here, we have reviewed some of the alterations and impacts that obesity may impose on the pathogenesis and clinical management of IBD. Conclusively, inflammatory processes of IBD are reinforced by obesity. Furthermore, as a two-way road, obesity can be caused by IBD. However, autoimmunity in IBD is not found to have a consistent relationship with obesity. Although, medical and surgical treatments of IBD are affected by obesity in terms of their efficacy and outcomes. The most important aspect of obesity that can influence the course of disease management is associated with significant disabilities that obesity may cause rather than a metabolic or molecular rationale.
Literatur
1.
2.
3.
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2005;2008(32):1431–7.
4.
Hu FB. Obesity and mortality: watch your waist, not just your weight. Arch Intern Med. 2007;167(9):875–6.PubMedCrossRef
5.
Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):8.CrossRef
6.
Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390–407.PubMedCrossRef
7.
Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol. 2005;3(10):992–6.PubMedCrossRef
8.
John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther. 2006;23(11):1511–23.PubMedCrossRef
9.
Olfatifar M, Zali MR, Pourhoseingholi MA, Balaii H, Ghavami SB, Ivanchuk M, et al. The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: a modeling study. BMC Gastroenterol. 2021;21(1):204.PubMedPubMedCentralCrossRef
10.
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78.CrossRef
11.
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448–54.PubMedCrossRef
12.
Baradaran Ghavami S, Chaleshi V, Derakhshani S, Aimzadeh P, Asadzadeh-Aghdaie H, Zali MR. Association between TNF-α rs1799964 and RAF1 rs1051208 MicroRNA binding site SNP and gastric cancer susceptibility in an Iranian population. Gastroenterology and hepatology from bed to bench. 2017;10(3):214–9.PubMedPubMedCentral
13.
Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–55.PubMedCrossRef
14.
15.
Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010;2010: 802078.PubMedPubMedCentralCrossRef
16.
Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease. Gastroenterology. 1999;117(1):73–81.PubMedCrossRef
17.
Baradaran Ghavami S, Mohebbi SR, Karimi K, Azimzadeh P, Sharifian A, Mojahed Yazdi H, et al. Variants in two gene members of the TNF ligand superfamily and hepatitis C virus chronic disease. Gastroenterol Hepatol Bed Bench. 2018;11(Suppl 1):S66-s72.PubMedPubMedCentral
18.
Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79(9):955–8.PubMedCrossRef
19.
Kredel LI, Batra A, Stroh T, Kühl AA, Zeitz M, Erben U, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013;62(6):852–62.PubMedCrossRef
20.
Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. Faseb j. 2002;16(10):1163–76.PubMedCrossRef
21.
Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol. 2002;23(4):182–7.PubMedCrossRef
22.
Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med. 2012;33(1):35–45.PubMedCrossRef
23.
Lam QL, Liu S, Cao X, Lu L. Involvement of leptin signaling in the survival and maturation of bone marrow-derived dendritic cells. Eur J Immunol. 2006;36(12):3118–30.PubMedCrossRef
24.
25.
De Rosa V, Procaccini C, Calì G, Pirozzi G, Fontana S, Zappacosta S, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007;26(2):241–55.PubMedCrossRef
26.
Sitaraman S, Liu X, Charrier L, Gu LH, Ziegler TR, Gewirtz A, et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. Faseb j. 2004;18(6):696–8.PubMedCrossRef
27.
Ekmekci H, Ekmekci OB. The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost. 2006;12(2):163–8.PubMedCrossRef
28.
Neumeier M, Weigert J, Schäffler A, Wehrwein G, Müller-Ladner U, Schölmerich J, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79(4):803–8.PubMedCrossRef
29.
Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301(4):1045–50.PubMedCrossRef
30.
Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323(2):630–5.PubMedCrossRef
31.
Kahraman R, Calhan T, Sahin A, Ozdil K, Caliskan Z, Bireller ES, et al. Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease? Ther Clin Risk Manag. 2017;13:1295.PubMedPubMedCentralCrossRef
32.
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(2):100–5.PubMedCrossRef
33.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12.PubMedCrossRef
34.
Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18(1):1–13.CrossRef
35.
Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19(12):1070–4.PubMedCrossRef
36.
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2007;19(9):789–94.PubMedCrossRef
37.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–30.PubMedCrossRef
38.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748–58.PubMedCrossRef
39.
Bertin B, Desreumaux P, Dubuquoy L. Obesity, visceral fat and Crohn’s disease. Curr Opin Clin Nutr Metab Care. 2010;13(5):574–80.PubMedCrossRef
40.
Gambero A, Maróstica M, Saad MJA, Pedrazzoli J Jr. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis. 2007;13(11):1357–64.PubMedCrossRef
41.
Lascano CA, Soto F, Carrodeguas L, Szomstein S, Rosenthal RJ, Wexner SD. Management of ulcerative colitis in the morbidly obese patient: is bariatric surgery indicated? Obes Surg. 2006;16(6):783–6.PubMedCrossRef
42.
Reinisch W, Gasché C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, et al. Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol. 1999;94(8):2156–64.PubMedCrossRef
43.
Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn’s disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis. 2000;15(4):206–10.PubMedCrossRef
44.
Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66:297–309.PubMedCrossRef
45.
Rupnick MA, Panigrahy D, Zhang C-Y, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci. 2002;99(16):10730–5.PubMedPubMedCentralCrossRef
46.
47.
Harpsøe MC, Basit S, Andersson M, Nielsen NM, Frisch M, Wohlfahrt J, et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol. 2014;43(3):843–55.PubMedCrossRef
48.
Matarese G, Leiter E, La Cava A. Leptin in autoimmunity: many questions, some answers. Tissue Antigens. 2007;70(2):87–95.PubMedCrossRef
49.
Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Silman AJ, Barrett EM, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 1997;40(11):1955–61.PubMedCrossRef
50.
Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology. 1994;5(5):525–32.PubMed
51.
Duntas LH, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23(6):646–53.PubMedCrossRef
52.
Armstrong A, Harskamp C, Armstrong E. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.PubMedPubMedCentralCrossRef
53.
Sterry W, Strober B, Menter A, Council IP. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649–55.PubMedCrossRef
54.
Chan SS, Luben R, Olsen A, Tjonneland A, Kaaks R, Teucher B, et al. Body mass index and the risk for Crohn’s disease and ulcerative colitis: data from a European prospective cohort study (TheIBDin EPIC Study). Am J Gastroenterol. 2013;108(4):575–82.PubMedCrossRef
55.
Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G. Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev. 2016;15(5):447–50.PubMedCrossRef
56.
Versini M, Jeandel P-Y, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981–1000.PubMedCrossRef
57.
Pringle PL, Stewart KO, Peloquin JM, Sturgeon HC, Nguyen D, Sauk J, et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn’s disease. Inflamm Bowel Dis. 2015;21(10):2304–10.PubMed
58.
Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci. 2015;60(8):2436–45.PubMedCrossRef
59.
Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside. Scotland Obesity facts. 2009;2(6):370–2.PubMedCrossRef
60.
Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015;30(2):237–42.PubMedCrossRef
61.
Seminerio JL, Koutroubakis IE, Ramos-Rivers C, Hashash JG, Dudekula A, Regueiro M, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(12):2857–63.PubMedCrossRef
62.
Fitzmorris PS, Colantonio LD, Perez ET, Smith I, Kakati DD, Malik TA. Impact of metabolic syndrome on the hospitalization rate of Crohn’s disease patients seen at a tertiary care center: a retrospective cohort study. Digestion. 2015;91(3):257–62.PubMedCrossRef
63.
Uko V, Vortia E, Achkar J-P, Karakas P, Fiocchi C, Worley S, et al. Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20(12):2286–91.PubMedCrossRef
64.
Li Y, Zhu W, Gong J, Zhang W, Gu L, Guo Z, et al. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn’s disease. Colorectal Dis. 2015;17(3):225–34.PubMedCrossRef
65.
Michalak A, Mosińska P, Fichna J. Common links between metabolic syndrome and inflammatory bowel disease: current overview and future perspectives. Pharmacol Rep. 2016;68(4):837–46.PubMedCrossRef
66.
Harper J, Welch M, Sinanan M, Wahbeh G, Lee S. Co-morbid diabetes in patients with Crohn’s disease predicts a greater need for surgical intervention. Aliment Pharmacol Ther. 2012;35(1):126–32.PubMedCrossRef
67.
Thompson NP, Wakefield AJ, Pounder RE. Prognosis and prognostic factors in inflammatory bowel disease. Saudi J Gastroenterol. 1995;1(3):129.PubMed
68.
Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003;3:81–92.PubMed
69.
70.
Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, et al. Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci. 2010;55(4):1066–78.PubMedCrossRef
71.
Poon SS, Asher R, Jackson R, Kneebone A, Collins P, Probert C, et al. Body mass index and smoking affect thioguanine nucleotide levels in inflammatory bowel disease. J Crohns Colitis. 2015;9(8):640–6.PubMedCrossRef
72.
Kent PD, Luthra HS, Michet C. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol. 2004;31(9):1727–31.PubMed
73.
Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, Steinman MA. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 2014;66(8):1159–66.CrossRef
74.
Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30.PubMedCrossRef
75.
Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019;35(4):302–10.PubMedPubMedCentralCrossRef
76.
Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, et al. Comparative effectiveness and safety of anti–tumor necrosis factor agents in biologic-naive patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2016;14(8):1120-1129.e6.PubMedPubMedCentralCrossRef
77.
Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, et al. Comparative effectiveness of infliximab and adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(5):811-817.e3.PubMedCrossRef
78.
Rodin I, Chan J, Meleady L, Hii C, Lawrence S, Jacobson K. High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease. JGH Open. 2020;4(3):446–53.PubMedCrossRef
79.
Bhalme M, Sharma A, Keld R, Willert R, Campbell S. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol. 2013;25(5):543–9.PubMedCrossRef
80.
Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2118–24.PubMedCrossRef
81.
Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West R, Kuipers E, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther. 2012;35(3):335–41.PubMedCrossRef
82.
Doyle SL, Lysaght J, Reynolds J. Obesity and post-operative complications in patients undergoing non-bariatric surgery. Obes Rev. 2010;11(12):875–86.PubMedCrossRef
83.
Makino T, Shukla PJ, Rubino F, Milsom JW. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection. Ann Surg. 2012;255(2):228–36.PubMedCrossRef
84.
Jain A, Limketkai BN, Hutfless S. Mo1243 The effect of obesity on post-surgical complications during hospitalizations for inflammatory bowel disease: a nationwide analysis. Gastroenterology. 2014;146(5):S-595-S−596.CrossRef
85.
Duchesne JC, Wang Y-Z, Weintraub SL, Boyle M. Stoma complications: a multivariate analysis/discussion. Am Surg. 2002;68(11):961.PubMed
86.
87.
Klos CL, Safar B, Jamal N, Hunt SR, Wise PE, Birnbaum EH, et al. Obesity increases risk for pouch-related complications following restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA). J Gastrointest Surg. 2014;18(3):573–9.PubMedCrossRef
88.
Kiran R, Remzi F, Fazio V, Lavery I, Church J, Strong S, et al. Complications and functional results after ileoanal pouch formation in obese patients. J Gastrointest Surg. 2008;12(4):668–74.PubMedCrossRef
89.
Ding Z, Wu XR, Remer E, Lian L, Stocchi L, Li Y, et al. Association between high visceral fat area and postoperative complications in patients with Crohn’s disease following primary surgery. Colorectal Dis. 2016;18(2):163–72.PubMedCrossRef
90.
Stidham RW, Waljee AK, Day NM, Bergmans CL, Zahn KM, Higgins PD, et al. Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn’s disease. Inflamm Bowel Dis. 2015;21(6):1306–13.PubMed
91.
Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PAJAJoP-E, Metabolism. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. 2004;287(1):E182-E7.
92.
Gruber L, Kisling S, Lichti P, Martin F-P, May S, Klingenspor M, et al. High fat diet accelerates pathogenesis of murine Crohn’s disease-like ileitis independently of obesity. 2013;8(8):e71661.
93.
Agus A, Planchais J, Sokol HJCh. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23(6):716–24.PubMedCrossRef
94.
Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediator Inflamm. 2014;2014:162011.CrossRef
95.
Canani RB, Di Costanzo M, Leone L, Pedata M, Meli R. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519.PubMedPubMedCentralCrossRef
96.
Zietek T. Intestinal nutrient sensing and blood glucose control. Curr Opin Clin Nutr Metab Care. 2015;18(4):381–8.PubMedCrossRef
97.
Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, Daly K, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci U S A. 2007;104(38):15075–80.PubMedPubMedCentralCrossRef
98.
Yadav H, Lee J-H, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288(35):25088–97.PubMedPubMedCentralCrossRef
99.
Miettinen T, Siurala M. Bile salts, sterols, sterol esters, glycerides and fatty acids in micellar and oil phases of intestinal contents during fat digestion in man. Z Klin Chem Klin Biochem. 1971;9(1):47–52.PubMed
100.
Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225–35.PubMedCrossRef
101.
Losurdo G, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, et al. Prevalence and associated factors of obesity in inflammatory bowel disease: a case-control study. World J Gastroenterol. 2020;26(47):7528.PubMedPubMedCentralCrossRef
102.
Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2003;98(7):1556–62.PubMedCrossRef
103.
Flores FA, Burstein E, Cipher DJ, Feagins LA. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci. 2015;60(8):2436–45.PubMedCrossRef
Metadaten
Titel
Obesity, a challenge in the management of inflammatory bowel diseases
verfasst von
Mohsen Rajabnia
Shideh Moftakhari Hajimirzaei
Mohammad Reza Hatamnejad
Shabnam Shahrokh
Shaghayegh Baradaran Ghavami
Maryam Farmani
Naghmeh Salarieh
Nastaran Ebrahimi
Nesa Kazemifard
Azam Farahanie
Ghazal Sherkat
Hamid Asadzadeh Aghdaei
Publikationsdatum
29.08.2022
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 6/2022
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-022-09315-7

Weitere Artikel der Ausgabe 6/2022

Immunologic Research 6/2022 Zur Ausgabe

Original Article

The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy

Original Article

The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma

Original Article

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis

Original Article

The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels

Original Article

5Apal, Taql, Fokl, and Bsml polymorphisms and the susceptibility of Behcet’s disease: an updated meta-analysis

Review

Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise